HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target

Benzinga · 12/02/2025 12:12
HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $6 price target.